Benzinga··Vandana SinghMerck Tumbles 4% as Cancer Trial Fails, Though HIV Approval Offers Lifeline
Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.
MRKEXELFDA approvalclinical trial failure